[Topical XXXX for the treatment of @entity9 : A first clinical observation. German version].

@entity1 @entity137 @entity2951 @entity8603 @entity1372 @entity3303 @entity86 @entity4216 @entity158 @entity14000 @entity9 @entity5923
BACKGROUND: @entity9 is difficult to treat and available options are frequently not sufficient. The expectorant @entity5923 also works as a strong local anesthetic and blocks @entity1372 channels about 40 times more potently than @entity3303 . @entity5923 preferentially inhibits the channel subtype @entity8603 , which is expressed particularly in nociceptive C  fibers. Due to the @entity137 , topical @entity5923 seemed to represent a reasonable therapeutic attempt for treatment of @entity9 resistant to other standard options. MATERIALS AND METHODS: Medical records of 7 @entity1 with severe @entity9 , in whom many attempts at treatment with approved substances were not sufficient or possible, are reported retrospectively. @entity1 were then treated with topical @entity5923 20   % cream applied in the area of @entity9 . RESULTS: Causes of @entity9 were @entity14000 (2-*), @entity4216 , @entity158 , @entity158 , @entity86 and an unclear allodynia of the foot. Mean @entity158 intensity was reported as 4-6/10 on a numeric rating scale (NRS) and maximum @entity158 intensity as 6-10/10. @entity158 following @entity5923 cream was 2-8 points (NRS) within 15-30  min and lasted 3-8  h. @entity158 attacks were reduced in all 5 @entity1 presenting this problem. Topical @entity5923 achieved @entity158 reduction in 4 @entity1 with no improvement after @entity3303 5   % and 1 @entity1 with no response to @entity2951 8   %. No adverse events or skin changes have been observed, and the longest treatment duration is currently 4 years. CONCLUSION: @entity5923 acts as a strong local anesthetic and preferentially inhibits the nociceptive-relevant @entity1372 channel subtype @entity8603 . For the first time, we report relevant @entity158 reduction following topical @entity5923 20   % cream in @entity1 with @entity9 . Regarding the advantageous profile with rare side effects, the clinical benefit for @entity158 @entity1 should be further investigated.
